logo
Plus   Neg
Share
Email

Biocon And Mylan's Biosimilar Trastuzumab Gets Approval In Brazil

Biosimilar Trastuzumab, co-developed by Biocon Ltd. and Mylan N.V. (MYL), has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.

Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer.

Libbs will commercialize the product in Brazil under the brand name Zedora, which will provide affordable access to a cutting-edge biologics therapy for patients in Brazil.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Reigniting concerns about a global trade war, President Donald Trump announced plans to impose new tariffs on billions of dollars worth of Chinese imports on Friday. Trump said in a statement the U.S. will implement a 25 percent tariff on $50 billion of goods from China that contain "industrially significant technologies." Investors may want to take note of shares of school bus maker Blue Bird Corp. (BLBD) that are 17% off their 52-week high of $24.99, and at an attractive price point. Significant growth potential in Alternative-Fuel offerings, product differentiation & upgrades, compelling industry attributes, growing profitability, rising interest in Electric Buses, and strong Free cash flow generation make this s A full-time minimum wage worker cannot afford a two-bedroom rental apartment anywhere in the U.S. despite the increase in state and city minimum wages, according to report from the National Low Income Housing Coalition or NLIHC. The NLIHC's "Out of Reach" 2018 annual report calculates the gap between wages and the costs of rental housing across the U.S.
Follow RTT